Last update 23 Jul 2025

Mirdametinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Mirdametinib (USAN), PD 901, PD-0325901
+ [3]
Action
inhibitors
Mechanism
MEK1 inhibitors(Dual specificity mitogen-activated protein kinase kinase 1 inhibitors), MEK2 inhibitors(Dual specificity mitogen-activated protein kinase kinase 2 inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
United States (11 Feb 2025),
RegulationPriority Review (United States), Fast Track (United States), Orphan Drug (United States), Orphan Drug (European Union), Conditional marketing approval (European Union), Rare Pediatric Disease (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC16H14F3IN2O4
InChIKeySUDAHWBOROXANE-SECBINFHSA-N
CAS Registry391210-10-9

External Link

KEGGWikiATCDrug Bank
D11675--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
NF1 mutant Plexiform Neurofibroma
European Union
18 Jul 2025
NF1 mutant Plexiform Neurofibroma
Iceland
18 Jul 2025
NF1 mutant Plexiform Neurofibroma
Liechtenstein
18 Jul 2025
NF1 mutant Plexiform Neurofibroma
Norway
18 Jul 2025
Neurofibromatosis 1
United States
11 Feb 2025
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Dedifferentiated LiposarcomaPhase 2
United States
19 Feb 2025
Myxoid LiposarcomaPhase 2
United States
19 Feb 2025
Advanced Malignant Solid NeoplasmPhase 2
United States
03 Feb 2023
Advanced Malignant Solid NeoplasmPhase 2
Australia
03 Feb 2023
Melanoma, Cutaneous MalignantPhase 2
United States
03 Feb 2023
Melanoma, Cutaneous MalignantPhase 2
Australia
03 Feb 2023
Low grade gliomaPhase 2
United States
21 Jun 2021
Plexiform NeurofibromaPhase 2
United States
29 Sep 2019
Colorectal CancerPhase 2
Netherlands
02 Apr 2014
KRAS mutant Non-small Cell Lung CancerPhase 2
Netherlands
02 Apr 2014
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
-
Mirdametinib capsule
nyxficsvvr(yknswrbvkk) = lrkmqfhejx wwsfdhpcjs (cfrhhugozo, 29% - 55%)
Positive
07 Apr 2025
Mirdametinib dispersible tablet
nyxficsvvr(yknswrbvkk) = kfghdtenpr wwsfdhpcjs (cfrhhugozo, 38% - 65%)
Phase 2
-
Mirdametinib capsules
upoqgsuhek(rwkpurmvhl) = jgekacmyrl kikcmamzld (spvuwxuekx )
Positive
20 Feb 2025
Mirdametinib tablets for oral suspension
upoqgsuhek(rwkpurmvhl) = ildxfmpyfb kikcmamzld (spvuwxuekx )
Phase 2
114
(adults)
awfkcptcku(ndqpgobmev) = Clinically meaningful improvement was defined as change from baseline >9.7 points for adults, >8.5 points for child self-report, and >9.0 points for parent proxy-report. PedsQL-TS improvement (least-squares mean, LSM [SE] change) from baseline at C13 was 3.9 (1.6; P=.018; n=34) for adults, 4.0 (2.4; P=.096; n=38) for children by self-report, and 5.6 (1.9; P=.005; n=43) by parent proxy-report. PedsQL-TS improvements for adults and children by parent proxy-report (not by children self-report) were observed early (at C5 and C3, respectively) and sustained through C24. Clinically meaningful improvement in PedsQL-TS from baseline at C13 was achieved by 37% (10/27) adults, 45% (13/29) children by self-report, and 47% (15/32) children by parent proxy-report (among patients who could have achieved a clinically meaningful change from baseline). Significant (P<.05) improvement from baseline to C13 was reported for physical (adults, children, and parent proxy-report), school/work (adults), and emotional and social (parent proxy-report) subscales. ouwibkjidw (xrtjwmozio )
Positive
11 Nov 2024
(children)
Phase 1
Low grade glioma
BRAF alteration | FGFR1 alteration | NF1 alteration ...
23
etezhtgzbw(btqvduenzh) = scsjizvnvo zrjcpslgbb (kgciewdiaa )
Positive
11 Nov 2024
Phase 2
114
(adults)
tkylkmiyza(ulcduzqvff) = esuvymsdro bjyzocupuv (sjbrhlroeg, 29 - 55)
Positive
11 Nov 2024
(children)
tkylkmiyza(ulcduzqvff) = cgyfuhnvht bjyzocupuv (sjbrhlroeg, 38 - 65)
Phase 2
12
(Prepubescent patients)
cpqcwzners(wdokkqgkdn) = ddtrbeboju azbebobzom (lhnoonreyu )
-
11 Nov 2024
Phase 2
114
Mirdametinib 2 mg/m^2 BID
ywqvlccajd(nopeyjgtbo) = bqxvcvansw ndczpacgtg (aoxlujlnjk, 29 - 55)
Positive
17 Oct 2024
Placebo
ywqvlccajd(nopeyjgtbo) = ysvgffgfpt ndczpacgtg (aoxlujlnjk, 38 - 65)
Phase 1/2
6
(Arm 1, Part 1 - Mirdametinib in Combination With Fulvestrant)
dujfcnmbsd(khzvysjfrs) = vmdefgogee pfqyiedqrk (wpymluglyq, kwotpzpimv - ivmzvhfumv)
-
09 Jul 2024
(Arm 1, Part 2 - Mirdametinib in Combination With Fulvestrant)
dujfcnmbsd(khzvysjfrs) = tdqxwdnpbd pfqyiedqrk (wpymluglyq, qtraazmmet - avorelqauv)
Phase 2
114
kxpylnpcmn(khntszxcer) = zqacarkqmt hwdpzcudee (edhzleufmf, 29 - 55)
Positive
24 May 2024
(pediatric)
kxpylnpcmn(khntszxcer) = sdmwvleobi hwdpzcudee (edhzleufmf, 38 - 65)
Phase 2
114
(pediatric patients)
cclsbgtrgk(bfbhbseabo) = uaemetwsvb rozfbheyec (lutqctwsdf )
Positive
16 Nov 2023
(adult patients)
cclsbgtrgk(bfbhbseabo) = bkaxmlhgfp rozfbheyec (lutqctwsdf )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free